Cure My Disease

Don't miss your cure!

 Log in / Sign up

New algorithm aims to stop dangerous bleeding in VWD patients

NCT ID NCT06651255

Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a step-by-step care plan (algorithm) can lower the chance of another serious stomach or nose bleed in people with von Willebrand disease. About 66 adults who have had such a bleed will be randomly assigned to either the new plan or standard care. The goal is to see if the algorithm helps prevent bleeds from coming back.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 66 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Mar 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males and females adults aged \> 18 years * With a constitutional von Willebrand Disease (according to the phenotypic criteria of the French Reference Center of von Willebrand Disease) * With a GI bleeding \[either overt (any hematemesis, any melena or hematochezia with at least a 2g/dL drop in hemoglobin) or occult (iron deficiency anemia with at least 2g/dL drop in hemoglobin)\] with the presence of angiodysplasia or a negative finding on digestive conventional endoscopy OR with a severe epistaxis (requiring red blood cells transfusion or treatment with VWF concentrates) * Be affiliated to a social security scheme * Written informed consent obtained Exclusion Criteria: * Acquired von Willebrand Disease * Presence of an inhibitor to VWF or a contra indication to VWF concentrates * Contra-indication to videocapsule endoscopy * Refusal of the procedures part of the study * Pregnant women or breastfeeding * Short-life expectancy * Liver cirrhosis Child-Pugh C or diagnosed portal hypertension * Cancer currently undergoing chemotherapy * Inability to provide informed consent * Patient under justice protection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Von Willebrand disease (VWD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

angiodysplasia Epistaxis Gastrointestinal Hemorrhage von Willebrand disease (hereditary or acquired)

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Von Willebrand disease (VWD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    17 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AP-HM Hôpital Timone

    NOT_YET_RECRUITING

    Marseille, 13005, France

  • AP-HP Hôpital Kremlin Bicetre

    NOT_YET_RECRUITING

    Le Kremlin-Bicêtre, 94270, France

  • CH Chambery

    NOT_YET_RECRUITING

    Chambéry, 73000, France

  • CHRU Brest

    NOT_YET_RECRUITING

    Brest, 29200, France

  • CHU Amiens

    NOT_YET_RECRUITING

    Amiens, 80000, France

  • CHU Caen

    NOT_YET_RECRUITING

    Caen, 14000, France

  • CHU Clermont-Ferrand

    NOT_YET_RECRUITING

    Clermont-Ferrand, 63000, France

  • CHU Dijon

    NOT_YET_RECRUITING

    Dijon, 21000, France

  • CHU Lille

    NOT_YET_RECRUITING

    Lille, Nord, 59000, France

  • CHU Montpellier

    RECRUITING

    Montpellier, 34000, France

  • CHU Nantes

    NOT_YET_RECRUITING

    Nantes, 44000, France

  • CHU Rennes

    NOT_YET_RECRUITING

    Rennes, 35000, France

  • CHU Rouen

    NOT_YET_RECRUITING

    Rouen, 76000, France

  • CHU Strasbourg

    NOT_YET_RECRUITING

    Strasbourg, 67000, France

  • CHU Toulouse

    NOT_YET_RECRUITING

    Toulouse, 31000, France

  • CHU Tours

    NOT_YET_RECRUITING

    Tours, Tours, 37000, France

  • Hôpital cardiologique Louis Pradel

    NOT_YET_RECRUITING

    Bron, 69500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.